

## NEWS RELEASE

**HYDERABAD, INDIA (8 Feb' 2022)** -- SUVEN Pharmaceuticals Limited ("SPL", "Company") today announced unaudited financial results for the quarter ended 31 Dec' 2021. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 8 Feb' 2022 at Hyderabad.

### Financial Snapshot

INR (Millions, except ratios and EPS)

	Quarter ended			Period ended		Year ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
Revenue	4,008.60	3,393.23	2,797.76	10,097.67	7,614.93	10,239.56
EBITDA	1,953.02	1,601.10	1,421.77	4,758.12	3,577.68	4,547.59
EBITDA Margin	48.72%	47.19%	50.82%	47.12%	46.98%	44.41%
EBIT	1,847.96	1,509.33	1,334.20	4,471.36	3,344.47	4,231.23
EBIT Margin	46.10%	44.48%	47.69%	44.28%	43.92%	41.32%
Finance costs	7.42	11.75	19.10	40.42	72.73	91.44
Depreciation	105.06	91.77	87.58	286.76	233.21	316.36
Taxes	470.59	345.60	338.75	1,094.59	829.79	1,053.32
Taxes to PBT	25.57%	23.08%	25.76%	24.70%	25.36%	25.44%
PAT (Standalone)	1,369.95	1,151.98	976.35	3,336.34	2,441.95	3,086.47
PAT Margin (Standalone)	34.18%	33.95%	34.90%	33.04%	32.07%	30.14%
Associate Company	-	174.63	160.00	411.12	350.70	537.36
PAT (Consolidated)	1,600.69	969.85	1,136.25	3,621.37	2,792.26	3,623.42
PAT Margin (Consolidated)	39.93%	28.58%	40.61%	35.86%	36.67%	35.39%
EPS (Standalore)	5.38	4.53	3.84	13.11	9.59	12.12
EPS (Consolidated)	6.29	3.81	4.46	14.23	10.97	14.23
Paid up share capital (Re.1/sh)	254.56	254.56	254.56	254.56	254.57	254.56

### Growth Ratios

	Quarter ended 31 Dec 21 to Quarter ended 30 Sep 21	Quarter ended 31 Dec 21 to Quarter ended 31 Dec 20	Period ended 31 Dec 21 to Period ended 31 Dec 20
Growth in income	18.14%	43.28%	32.60%
Growth in EBIDTA	21.98%	37.37%	32.99%
Growth in EBIT	22.44%	38.51%	33.69%
Growth in PAT Standalone	18.92%	40.31%	36.63%
Growth in PAT Consolidated	65.05%	40.87%	29.69%

- The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
- The Suven Pharma Inc., the WOS of our Company has divested its entire stake (25% amounting to \$35.00 Mn) in M/s Rising Pharma Holdings, Inc., USA on 13th Dec,2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, a leading global alternative investment firm in USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of \$ 41.555 Mn and a stake valued at \$15.803 Mn in Raisin Aggregators L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Dec'2021.

## Suven Pharmaceuticals Limited

3. The Board has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 2.00 per equity share (200% of Face value of Rs.1.00), totaling to Rs. 3.00 per equity share (300% of Face value of Rs. 3.00 each) for the financial year 2021-22.
4. The Board in its meeting held on 8th February 2022, has given its in-principle approval to evaluate the acquisition opportunity of Caper Pharma Pvt. Ltd., an SEZ unit in Hyderabad engaged in Formulations. The Company will evaluate the proposal subject to financial, tax and legal due diligence to finalize the definitive agreements.
5. The COVID-19 continuous to impact the business and research operations in India and our wholly owned subsidiary, Suven pharma, Inc., USA.

**For more information, please visit: <http://www.suvenpharm.com>**

**Risk Statement:**

*Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.*

## **Suven Pharmaceuticals Limited**